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Estimating Global Epidemiology 
of Low-Pathogenic Human 
Coronaviruses in Relation to the 
COVID-19 Context
To the Editor—Coronaviruses (CoV) 
comprise a large family of zoonotic RNA 
viruses. Among the 7 members known to 
infect humans, SARS-CoV-2, the causa-
tive agent of COVID-19, together with 
SARS-CoV and MERS-CoV, cause se-
vere respiratory syndrome. The other 
4 members, including NL63, HKU1, 
OC43, and 229E, are widely circulating 
in humans but predominantly cause 
mild respiratory tract illness [1]. Thus 
we call these 4 viruses low-pathogenic 
human CoVs (LPH-CoV). Two recent 
studies by Nickbakhsh et  al and Monto 
et al in The Journal of Infectious Diseases 
have reported the prevalence of LPH-
CoV as 4.0% in western Scotland and 
8.3%–16.3% in Michigan, United States 
[2, 3]. Interestingly, both studies de-
tected the highest frequency of infection 
in children younger than 5  years. This 
is the opposite to the COVID-19 pan-
demic where children are less commonly 
affected by SARS-CoV-2 [4]. These in-
triguing findings trigger important hy-
potheses on whether coinfection with 
LPH-CoV interferes with SARS-CoV-2 
or exposure to LPH-CoV confers cross-
protective immunity to some extent.
As COVID-19 is currently affecting 
the global population and research on 
LPH-CoV has been largely neglected in 
the past, we attempted to perform a sys-
tematic review and meta-analysis to map 
the global epidemiology of LPH-CoV. 
LPH-CoV–related studies from 1990 to 
March 2020 were systematically searched 
in Medline, Embase, Web of Science, 
Cochrane Central Register of Controlled 
Trials (CENTRAL), and Google scholar. 
Studies were included and data extracted 
only if they reported participants with 
symptoms of acute respiratory tract in-
fections or influenza like illness. A 95% 
confidence interval (95% CI) was es-
timated using Wilson score method. 
Pooled prevalence (detection rate) was 
calculated using the DerSimonian-Laird 
random-effects model with Freeman-
Tukey double arcsine transformation. 
In total, 128 studies with 205  421 in-
dividuals were included, and an overall 
infection rate was estimated as 5.21% 
(95% CI, 4.62%–5.83%; I2  =  97%). The 
prevalence of LPH-CoV varied sub-
stantially among the reported 44 coun-
tries, from 0.73% (Philippines; 95% CI, 
0.09%–1.84%) to 21.51% (Tunisia; 95% 





















































































































































































































































Figure 1. A, Global prevalence of LPH-CoV. The rate was determined as positive cases in tested populations with respiratory illness or symptoms. B, Forest plot of LPH-CoV 
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The number of available studies was very 
limited and many studies had small pop-
ulation sizes. This likely caused bias in 
prevalence estimations. Furthermore, 
similar to the studies of Nickbakhsh 
et al and Monto et al [2, 3], our included 
studies only detected LPH-CoV in indi-
viduals with respiratory illness or symp-
toms. This suggests that the prevalence 
rate of LPH-CoV in the general popu-
lation could be even lower, raising the 
question of how large the impact could 
be on COVID-19.
Monto et al have nicely presented the 
seasonal distribution of the identified 
cases in Michigan according to the 4 
LPH-CoV types [3]. We performed sim-
ilar analyses by pooling 5 studies with 
relevant data, and all these studies were 
from countries in the northern hemi-
sphere. We confirmed their findings that 
more cases were detected in the winter 
season (Figure 1C). However, we are cau-
tious about the interpretation of these 
seasonal distribution data (Figure  1C) 
[3] because they only specified the iden-
tified cases and not the rate of infection, 
as the total number of tested cases in each 
month was not given. More importantly, 
whether SARS-CoV-2 will develop into a 
seasonal and/or endemic virus only time 
will tell [3].
In summary, we have comprehensively 
estimated the global prevalence of LPH-
CoV among 44 countries and mapped 
their seasonal distribution. Our results 
further strengthen the epidemiological 
findings of Nickbakhsh et al and Monto 
et  al, but also raise cautions about the 
interpretation of existing data. We agree 
that continued and enhanced monitoring 
of circulating HLP-CoV is necessary to 
understand how they may have an im-
pact on the epidemiology and outcome of 
COVID-19 [5, 6].
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Reply to Li et al
To the Editor—We read with interest 
the letter by Li et al [1] reporting on the 
global prevalence of endemic human 
coronaviruses. The last decade has wit-
nessed an expansion of global surveil-
lance efforts in influenza and respiratory 
syncytial virus infections, leading to 
an increased recognition of the impor-
tance of these viruses, particularly in 
low- and middle-income settings [2]. 
However, a paucity of epidemiological 
research exists for other respiratory vir-
uses, as highlighted by the World Health 
Organization’s Battle Against Respiratory 
Viruses initiative [3].
Such knowledge is currently hin-
dered by the lack of capacity of many 










 user on 04 August 2020
